Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers.

ABSTRACT: Interleukin-15 (IL-15) promotes the survival of T lymphocytes and enhances the antitumour properties of chimeric antigen receptor (CAR) T cells in preclinical models of solid neoplasms in which CAR T cells have limited efficacy^1-4. Glypican-3 (GPC3) is expressed in a group of solid cancers^5-10, and here we report the evaluation in humans of the effects of IL-15 co-expression on GPC3-expressing CAR T cells (hereafter GPC3 CAR T cells). Cohort 1 patients ( NCT02905188 and NCT02932956 ) received GPC3 CAR T cells, which were safe but produced no objective antitumour responses and reached peak expansion at 2 weeks. Cohort 2 patients ( NCT05103631 and NCT04377932 ) received GPC3 CAR T cells that co-expressed IL-15 (15.CAR), which mediated significantly increased cell expans

SUBMITTER: Steffin D 

PROVIDER: S-EPMC12704925 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature